Today, an increasing number of cancer patients are favoring oral treatment with FXa inhibitors as the first choice for anticoagulation, because of an expected better adherence and more convenient usage (tablets versus injections), provided their risk of bleeding permits it. The gene discussed is F10; the disease is cancer.